Vorinostat is a histone deacetylase inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. MedsAcross supplies Vorinostat for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
Source: US FDA prescribing information
Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC 50 <86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of proteins, including histones and transcription factors. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones is associated with a condensed chromatin structure and repression of gene transcription. Inhibition of HDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in an open chromatin structure and transcriptional activation.
Source: US FDA prescribing information
400 mg orally once daily with food. If patient is intolerant to therapy, reduce the dose to 300 mg orally once daily with food. If necessary, reduce the dose further to 300 mg once daily with food for 5 consecutive days each week. Reduce dose in patients with mild or moderate hepatic impairment.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Thromboembolism: Monitor for pertinent signs and symptoms of pulmonary embolism and deep vein thrombosis. Myelosuppression: Thrombocytopenia and anemia may require dose modification or discontinuation. Monitor blood counts every 2 weeks during the first 2 months of therapy and monthly thereafter. Gastrointestinal Toxicity: Nausea, vomiting and diarrhea, patients may require antiemetics, antidiarrheals, and fluid and electrolyte replacement to prevent dehydration. Hyperglycemia: Monitor blood glucose every 2 weeks during the first 2 months of therapy and monthly thereafter. Clinical Chemistry Abnormalities: Measure and correct abnormal electrolytes, creatinine, magnesium and calcium at baseline. Monitor every 2 weeks during the first 2 months of therapy and at least monthly during treatment.
Source: US FDA prescribing information
The following serious adverse reactions have been associated with ZOLINZA in clinical trials and are discussed in greater detail in other sections of the label: Thromboembolism Myelosuppression Gastrointestinal Toxicity Hyperglycemia Clinical Chemistry Abnormalities Severe thrombocytopenia when combined with other Histone Deacetylase (HDAC) Inhibitors The most common adverse reactions (incidence ≥20%) are diarrhea, fatigue, nausea, thrombocytopenia, anorexia and dysgeusia.
Source: US FDA prescribing information
Coumarin-derivative anticoagulants: Prolongation of prothrombin time and International Normalized Ratio (INR) have been observed with concomitant use. Monitor INR frequently.
Source: US FDA prescribing information
Store at 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Vorinostat, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Zolinza 100 mg capsuleOral | Merck Sharp & Dohme | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Vorinostat in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Vorinostat and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Vorinostat, including Zolinza.
Yes. The US FDA first approved Vorinostat on 6 October 2006, according to Drugs@FDA.
No listed presentation of Vorinostat is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Vorinostat is classified under ATC code L01XX38 (Vorinostat).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.